ABSTRACT: Up to 11% of patients presenting with acute coronary syndromes undergo coronary artery bypass grafting. Guidelines largely recommend a one-size-fits-all preoperative discontinuation period for P2Y 12 receptor blockers to avoid bleeding. These recommendations do not account for highly variable pharmacodynamic responsiveness and for variable recovery of platelet reactivity following discontinuation of P2Y 12 receptor blockers. Several observational studies have demonstrated that an objective measurement of platelet function among these patients may reduce the waiting period while mitigating the risk of bleeding. Based on these findings, 2 recent guidelines included a Class IIa and IIb recommendation for platelet function testing in patients undergoing cardiac surgery. The following review article describes the rationale for discontinuation of dual antiplatelet therapy before cardiac surgery and the limitations with this approach, available platelet function assays to assess pharmacodynamic effects, and the association between platelet inhibition and other clinical factors with surgery-related bleeding. The information will assist the reader in determining which patients undergoing cardiac surgery might benefit from preoperative platelet function monitoring. U p to 11% of patients presenting with acute coronary syndromes (ACSs) will be referred for coronary artery bypass grafting (CABG). CABG following ACS occurs during a period when dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 receptor inhibitor is recommended and commonly administered.
U
p to 11% of patients presenting with acute coronary syndromes (ACSs) will be referred for coronary artery bypass grafting (CABG). CABG following ACS occurs during a period when dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 receptor inhibitor is recommended and commonly administered. 1, 2 Although preoperative P2Y 12 receptor inhibitor therapy has been associated with a reduction in the risk of ischemic event occurrences, recent P2Y 12 receptor inhibitor exposure increases the risk of surgery-related bleeding. 1, 3, 4 Surgical site bleeding has been shown to be associated with an elevated risk of infection. A substantial body of evidence supports a graded association between major surgery-related bleeding and 30-day mortality and morbidity after cardiac and noncardiac surgery. [5] [6] [7] [8] [9] [10] Potential explanations for the latter association are discontinuation of antiplatelet drugs, reduced oxygen delivery attributable to protracted bleeding, complications from reoperation for bleeding, and adverse effects of transfusion, such as hemolytic and immunologic reactions, transmission of infectious diseases, transfusion-related acute lung injury, or transfusion-associated circulatory overload. 8, 11, 12 To attenuate the risk of surgery-related bleeding in patients on P2Y 12 receptor inhibitors presenting for nonemergent major surgery, current guidelines recommend a one-size-fits-all preoperative discontinuation period of at least 3 to 5 days for ticagrelor, 5 days for clopidogrel, and 7 days for prasugrel (Table 1) , based largely on the results of large-scale clinical studies. [13] [14] [15] [16] The recommendation for a standardized preoperative waiting period accounts for neither highly variable pharmacodynamic responsiveness nor variability in platelet reactivity recovery time for clopidogrel, the most widely used P2Y 12 receptor blocker. 17 Therapy with prasugrel and ticagrelor has been associated with less variability in pharmacodynamic effects than clopidogrel, but the recovery of platelet function after prasugrel and ticagrelor is also variable. [18] [19] [20] Although ischemic event occurrence rates in the ≥5 days of antiplatelet drug withdrawal period before CABG are low, surgical preferences vary considerably regarding optimal duration of withdrawal, and surgical delays have important economic implications and are inconvenient for patients. 21 ,22
RATIONALE FOR DAPT AND PLATELET FUNCTION TESTING IN PATIENTS UNDERGOING SURGERY
On vascular injury induced by percutaneous coronary intervention and surgery, platelet adhesion to newly exposed collagen and von Willebrand Factor by specific platelet surface receptors at the site of damaged endothelium and the binding of thrombin generated by tissue factor to protease-activated receptors cause initial platelet activation. Following activation, ADP is released from platelet-dense granules. Thromboxane A 2 is generated from arachidonic acid by the activity of thromboxane synthase on prostaglandin H 2 , an intermediate formed by cyclooxygenase (COX)-1. Although both thromboxane A 2 and ADP amplify platelet activa- 23 During hemostasis, platelet adherence to the injured vascular wall is essential to prevent excessive bleeding (primary hemostasis), whereas uncontrolled platelet-rich thrombus formation in patients with ACS leads to vascular occlusion and subsequent ischemic event occurrences (Figure 1) . 24, 25 Therefore, DAPT with aspirin and a P2Y 12 receptor blocker is the most important pharmacological therapy administered to patients who have high-risk coronary artery disease to block platelet activation and reactivity and to prevent recurrent ischemic event occurrence. However, because of the variable response to P2Y 12 receptor blockers, patients with high on-treatment platelet reactivity to ADP are at an increased risk for ischemic event occurrences, and patients with low platelet reactivity to ADP are at an increased risk for bleeding. 22, 26 The largest body of data linking on-treatment platelet reactivity and a therapeutic window are in the percutaneous coronary intervention population. 27 These data provide the rationale for the study of the same in the surgical patient. Evidence from translational research studies suggests a therapeutic window concept for ADP-induced platelet reactivity in patients on DAPT after percutaneous coronary intervention. 22, 27, 28 In 20 839 patients on DAPT after percutaneous coronary intervention, a recent collaborative observational analysis sought to evaluate the prognostic value of low, optimal, and high platelet reactivity by applying uniform cutoff values for standardized assays. Patients with high platelet reactivity had a significant 2.73-fold increased relative risk of stent thrombosis and a significant 16% relative reduced risk of bleeding in comparison with those with optimal platelet reactivity. In contrast, patients with low platelet reactivity had a significant 1.74-fold increased relative risk for bleeding without a protective association with stent thrombosis. 28 Based on the high variability in on-treatment reactivity to ADP, and also in platelet function recovery, preoperative platelet function monitoring may identify those patients with high platelet reactivity who are candidates to proceed to surgery without delay, whereas those with low platelet Following cardiac surgery, platelet adhesion to newly exposed collagen and von Willebrand Factor by specific receptors at the site of damaged endothelium and the binding of thrombin generated by tissue factor to PARs cause initial platelet activation. Three important pathways (thrombin-protease-activated receptor-1, TxA 2 -thromboxane receptor, and ADP-P2Y 12 receptor) amplify the response. The ADP-P2Y 12 interaction plays a central role. HPR and LPR to ADP has been shown to be associated with ischemic events and bleeding in patients who have undergone percutaneous coronary intervention. COX-1 indicates cyclooxygenase-1; GPIIb/ IIIa, glycoprotein IIb/IIIa; HPR, high platelet reactivity; LPR, low platelet reactivity; PAR, protease-activated receptor; TP, thromboxane; and TxA 2 , thromboxane A 2 . 
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CURRENTLY AVAILABLE PLATELET FUNCTION ASSAYS
Platelet function assays that are used in the cardiac surgery area are described here (Table 2 ). Light transmittance aggregometry (LTA) is the gold standard to measure platelet function. In this method, the change in light transmittance in platelet-rich plasma following aggregation in response to various agonists is measured. LTA is a laborious method requiring skilled technicians, time, and a relatively large amount of blood in comparison with other methods. 31 The Multiplate analyzer (Dynabyte) is a whole-blood platelet aggregation assay. In this assay, electric impedance following adherence and aggregation of activated platelets on electrodes in response to various agonists is measured and recorded as area under the curve × minutes. 32 Advantages of this whole-blood assay are reduced blood sample handling, unchanged cellular environment, and rapid evaluation of platelet aggregation. This test is less widely used than the VerifyNow assay. Intra-and interassay variabilities and standardization of the Multiplate analyzer are its main disadvantages. It is not a true point-of-care assay and requires sample handling.
The VerifyNow assay (Acrriva Diagnostics) is a point-of-care, turbidimetric-based optical detection system that can be used to assess antiplatelet response to aspirin and P2Y 12 inhibitors in whole blood. In this assay, the change in light transmittance following binding of agonist-stimulated platelets to the fibrinogen-coated beads is measured and recorded as P2Y 12 reaction units or aspirin resistance units depending on the agonist used. Thrombelastography/thromboelastometry is an alternative testing strategy that provides real-time information on the viscoelastic properties of the evolving clot from the time of initial platelet-fibrin clot formation to clot strengthening to clot lysis. This assay therefore provides information on the (1) speed of clot generation (reaction time), a measure of enzymatic part of coagulation; (2) clot strength, a measure of platelet and fibrin contribution to the clot; and (3) clot stability, a function of fibrinolysis. This assay requires sample handling and is associated with assay variability. Long sample turnaround time (>30 minutes) and complex data output are other limitations of this assay. 34 Currently, 2 methods, the thromboelastography (TEG; Haemonetics Inc) system and thromboelastometry (ROTEM; Instrumentation Laboratory) are available. As described above, the underlying principles in these assays differ, and hence a poor correlation between these assays has been reported. 35, 36 TEG6S is a point-of-care assay based on microfluidics technology and is approved by the Food and Drug Administration in the United States. Other, less widely used assays in the cardiac surgery research area are Platelet Function Analyzer-100, flow cytometrybased assays, and the Cone and Platelet Analyzer.
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ROLE OF ASPIRIN THERAPY IN PATIENTS UNDERGOING CARDIAC SURGERY
Aspirin is the cornerstone of antiplatelet therapy for the secondary prevention of myocardial infarction. Aspirin reduces mortality and ischemic events and improves early venous graft patency after CABG. 40, 41 Following CABG, uninterrupted life-long low-dose aspirin therapy has been recommended in various guidelines. In comparison with low-dose aspirin regimens (75-150 mg), medium-dose regimens (300-325 mg) may be more effective in preventing graft occlusion and events in patients during the first year after CABG. 42 The antithrombotic property of aspirin is primarily attributed to irreversible acetylation of the platelet COX-1 enzyme. Subsequently, the generation of thromboxane A 2 and thromboxane A 2 -induced platelet aggregation are inhibited. In compliant patients, aspirin effectively blocks COX-1 activity, as indicated by COX-1-specific assays. Higher estimates of aspirin resistance reported in the literature are largely attributable to assays that are COX-nonspecific. 43 Studies associating aspirin-induced platelet inhibition and CABGrelated bleeding are lacking.
Noncompliance or withdrawal of aspirin has been associated with a 3-fold relative increased risk of major adverse ischemic events in a meta-analysis including 50 279 patients with coronary artery disease. 44 In a meta-analysis including 2399 patients undergoing CABG, preoperative use of aspirin significantly reduced the relative risk of myocardial infarction by 46% at the cost of a nearly 2-fold relative risk of surgical re-exploration. 45 In a recent randomized controlled trial involving 2100 low-risk patients undergoing CABG, aspirin did not reduce the composite of death and thrombotic complications (19.3% versus 20.4%) or increase major hemorrhage (1.8% versus 2.1%) in comparison with placebo. It is noteworthy that 50% of the patients in each group received tranexamic acid intraoperatively. 46 Tranexamic acid has antifibrinolytic properties and has been proposed to preserve platelet function by mitigating the effect of plasmin on the glycoprotein Ib receptor. 47 Current guidelines recommend preoperative continuation of aspirin "if the bleeding risk allows" and if aspirin is held to resume as soon as possible postoperatively. 16 In patients at high risk for bleeding or refusing blood transfusions and undergoing noncoronary cardiac surgery, the current guidelines suggest to consider stopping aspirin at least 5 days preoperatively (Table 1) .
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DAPT IN PATIENTS UNDERGOING CARDIAC SURGERY
There is accumulating evidence indicating increased CABG-related bleeding with enhanced platelet inhibition, albeit using different bleeding definitions. The TRI-TON TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction) demonstrated a 4-fold increased incidence of CABG-related major bleeding in patients randomly assigned to prasugrel in comparison with those randomly assigned to clopidogrel (13.4% versus 3.2%; P<0.001). Although chest tube blood loss was significantly higher with prasugrel than with clopidogrel, red blood cell (RBC) transfusion or the total donor exposure was similar between the 2 groups. 3, 48 In contrast, the PLATO trial (Platelet Inhibition and Patient Outcomes) revealed a similar incidence of CABG-related major bleeding (7.4% versus 7.9%) without any difference in chest tube drainage between patients randomly assigned to ticagrelor in comparison with clopidogrel. 1, 49 Four recent meta-analyses including up to 22 584 patients undergoing cardiac surgery evaluated risks and benefits of preoperative P2Y 12 receptor inhibitors. In comparison with P2Y 12 receptor inhibitor-naive patients and patients with early preoperative drug discontinuation (≥5 days), those with late preoperative drug discontinuation (<5 days) demonstrated a consistent 2-fold increased relative risk of reoperation for bleeding and a 50% increased relative mortality risk but some degree of protection against major ischemic cardiac events in patients with ACS. [50] [51] [52] [53] Specifically, one of these meta-analyses including observational studies demonstrated a 37% relative reduced risk (95% CI, 0.48-0.82) of immediate postoperative myocardial infarction in patients who received clopidogrel before CABG versus controls. 50 The latter observation suggests an anti-ischemic benefit of P2Y 12 receptor blocker with some degree of platelet inhibition. However, the results of these meta-analyses are encumbered by the inclusion of mainly nonrandomized and, in part, retrospective studies, variable P2Y 12 receptor inhibitor washout periods, the inherent limitations in the diagnosis of postoperative myocardial infarction in patients with ACS, and substantial heterogeneity among studies. [50] [51] [52] [53] [54] In 2011, a standardized Bleeding Academic Research Consortium (BARC) definition was introduced with the objective to compare bleeding events in cardiovascular clinical trials. BARC-4 bleeding refers to CABG-related bleeding and is characterized by at least 1 of the following: perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy for the purpose of controlling bleeding, transfusion of ≥5 U of packed RBCs within a 48-hour period, and chest tube output ≥2 L within a 24-hour period. 55 In a nationwide registry including 2244 ACS patients undergoing CABG, Hansson et al 9 recently demonstrated the benefits of the reversibility of ticagrelor effect in comparison with clopidogrel. Although the incidence of BARC-4 bleeding was similarly high when the washout period for ticagrelor or clopidogrel was <24 hours (38% versus 31%), ticagrelor-treated patients received more transfusions. However, there was a continuous decrease in BARC-4 bleeding with increasing days off clopidogrel, but there was no difference in BARC-4 bleeding beyond a 3-day washout period in ticagrelortreated patients. There was, overall, a lower incidence of major bleeding in the ticagrelor group (12.9% versus 17.6%; adjusted odds ratio, 0.72; 95% CI, 0.56-0.92; P=0.012). The authors attribute the sharp decline in BARC-4 bleeding after a 72-hour washout period of ticagrelor to the rapid recovery of platelet function.
ROLE OF PLATELET FUNCTION MONITORING IN PATIENTS UNDERGOING CABG Association Between On-Treatment Platelet Reactivity to ADP and CABGRelated Bleeding
A number of small observational studies performed in heterogeneous patient populations on DAPT suggest a graded association between preoperatively measured platelet reactivity levels and increased onpump and off-pump cardiac surgery-related bleeding (Table 3) . 18, [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] In 100 prospectively evaluated patients with recent exposure to DAPT and undergoing highly standardized off-pump CABG performed by 1 surgeon, Kwak et al 58 demonstrated an association between clopidogrel responsiveness and bleeding, irrespective of whether DAPT was discontinued 1 or 3 days preoperatively. Blood samples were taken immediately before the induction of anesthesia. It is important to note that patients in the highest tertile of platelet inhibitory response to clopidogrel as assessed by the TEG Platelet Mapping Assay (>76.5% inhibition) had a higher chest tube output and higher transfusion requirements than patients in the other 2 tertiles. In a multivariable analysis, only the third tertile remained independently associated with increased transfusion of allogenic blood products, with an adjusted relative risk of 11 for transfusion. Receiver-operating characteristic curve analysis identified 70% platelet inhibition as the optimal cutoff for transfusion requirement with an area under the curve of 0.71.
Ranucci and colleagues 62 retrospectively evaluated the association between platelet inhibition and bleeding in 361 patients undergoing various cardiac surgical procedures within a mean of 4 days since last DAPT. In this study, platelet function was assessed by Multiplate, using the ADP test and the thrombin receptoractivating peptide test, and blood samples were taken on the day of surgery. All patients received tranexamic acid. Severe bleeding, occurring in 7.5% of the patients, was defined according to the Universal Definition of Perioperative Bleeding as the presence of at least one of the following: 12-hour chest tube drainage >1 L, need for surgical re-exploration, and need for >5 U of RBCs or fresh frozen plasma. 68 It is notable that bleeding remained unchanged within a wide range of normal platelet aggregation but rapidly increased with low platelet reactivity. Receiver-operating characteristic curve analysis identified an optimal cutoff ≥22 U for the ADP test and ≥75 U for the thrombin receptor-activating peptide test, albeit with an area under the curve of only 0.62% and 0.65%, respectively. The negative predictive value for ADP and thrombin receptor-activating peptide test was 94% and 95%, respectively, and the positive predictive values of both tests were 20% and 23%, respectively, underlining the multifactorial nature of postoperative surgery-related bleeding. In multivariable logistic regression analysis, defined cutoffs of platelet inhibition remained significantly associated with bleeding; in addition, isolated CABG resulted in less bleeding than other types of cardiac surgery. 62 It is notable that the cutoff for the ADP test, as identified by Ranucci et al, 62 was only slightly higher than the low platelet reactivity associated with increased bleeding in patients with coronary artery disease after stenting. 22, 28 Similarly, Malm et al 18 identified an optimal cutoff of ADP-induced aggregation of 22 U (area under the curve, 0.73%; 95% CI, 0.63-0.84; P<0.001) determined by the Multiplate assay for severe bleeding as defined by the Universal Definition of Perioperative Bleeding in 90 prospectively evaluated patients undergoing CABG within 5 days of last ticagrelor intake. 68 Platelet function testing was performed after the induction of anesthesia. All patients received tranexamic acid. Severe bleeding occurred in 36% of the patients. Patients on DAPT randomly assigned to preoperative platelet function as part of a post-CPB transfusion algorithm bleed less than those patients managed without such an algorithm.
AA indicates arachidonic acid; AUC, area under the curve; ASPI, arachidonic acid-stimulated platelet inhibition; BMI, body mass index; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; DAPT, dual antiplatelet therapy; LTA, light transmittance aggregometry; MA, maximum amplitude; MA ADP , ADPinduced platelet-fibrin clot strength; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; PRU, P2Y 12 reaction units; PFA, platelet function analyzer; ROC, receiver operator characteristic curve; RBC, red blood cell; RCT, randomized clinical trial; TEG, thromboelastography; TIMI, thrombolysis in myocardial infraction; TRAP, thrombin receptor-activating peptide; and VASP-PRI, vasodilator-stimulated phosphoprotein phosphorylation assay.
The negative predictive value for this cutoff was 85%, and the positive predictive cutoff was 65%. A multivariable analysis accounting for potential confounders, however, is lacking in this study. 18 Different sensitivity/specificity and positive predictive value/negative predictive value of the 2 studies may be explained by the different incidence of severe bleeding (7.5% versus 36%) and the different distribution of platelet inhibition; 10% versus 42% of the patients of these 2 studies had a platelet inhibition below 22 U. The reported differences in negative predictive values and particularly positive predictive values emphasize the current limitations of predicting surgery-related bleeding merely based on measured platelet inhibition and support the need for large-scale, well-controlled validation studies to provide reproducible bleeding cutoffs.
Recently, our group prospectively evaluated the association between tertile distribution of preoperative on-treatment platelet reactivity as assessed by LTA, Multiplate analyzer, vasodilator-stimulated phosphoprotein phosphorylation assay and Innovance PFA2Y, and bleeding in 149 high-risk patients (additive EuroS-CORE: 8.4±4.3) undergoing isolated on-pump CABG within 48 hours of last DAPT, including prasugrel and ticagrelor. All patients received tranexamic acid, and standardized transfusion triggers were used unless there was active bleeding. The primary end point was the perioperative RBC loss calculated as follows: (blood volume×preoperative hematocrit×0.91) -(blood volume×hematocrit×0.91 on postoperative day 5) + (milliliters of transfused RBCs×0.59). Calculated RBC loss has been used as an end point previously and accounts both for hidden blood loss in a hematoma and for preoperative anemia, occurring in ≈20% of patients undergoing cardiac surgery. 69 Overall RBC (interquartile range) loss was 1196 (937-1572) mL, and 48% of the patients sustained BARC-4 bleeding. Specifically, calculated RBC loss, BARC-4 bleeding, 24-hour chest tube drainage, and RBC and platelet transfusion decreased with increasing tertiles of platelet reactivity as assessed by LTA (% ADP-induced aggregation, first tertile, 0-13.7; second tertile, 13.7-25; third tertile, 25-100). Similarly, transfusion of RBCs and platelets decreased with increasing platelet reactivity as assessed by vasodilator-stimulated phosphoprotein phosphorylation assay (platelet reactivity index %, first tertile, 0-26.8; second tertile, 26.8-65; third tertile, 65-100). In comparison with patients with a closure time ≥300 seconds, those with a closure time <300 seconds had a lower incidence of BARC-4 bleeding and lower transfusion rates of RBCs and platelets. A multivariable analysis identified tertile distribution of platelet inhibition, comorbidity, as reflected by the EuroSCORE, aspirin dose, and cardiopulmonary time as significant predictors of CABG-related bleeding. It is noteworthy that, in this patient population, every additional hour on cardiopulmonary bypass increased RBC loss by ≈25%, whereas the second and third tertile of platelet reactivity decreased RBC loss by 30% and 40%, respectively, suggesting decreased bleeding with increasing platelet function recovery and short bypass times.
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Individualized Preoperative Waiting Based on Platelet Function Monitoring
An individualized strategy for preoperative clopidogrel cessation based on preoperative platelet function testing has been demonstrated to reduce both preoperative waiting and CABG-related bleeding. 29, 30 The TARGET CABG study (Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG), a nonrandomized prospective study, demonstrated that stratifying patients on clopidogrel therapy into time-based platelet function recovery groups as determined by a preoperative TEG platelet-mapping assay resulted in similar bleeding (chest tube output and RBC transfusion) in comparison with those of clopidogrel-naive patients undergoing an elective first time on-pump CABG ( Figure 2 ). All patients were on aspirin therapy that was continued until surgery. Surgery was scheduled within 1 day in those with an ADP-induced platelet-fibrin clot strength >50 mm (high platelet reactivity), within 3 to 5 days in those with an ADP-induced platelet-fibrin clot strength 35 to 50 mm (intermediate platelet reactivity), and after 5 days in those with an ADP-induced platelet-fibrin clot strength <35 mm (low platelet reactivity). In the absence of a validated bleeding cutoff, we hypothesized that a cutoff associated with the short-and long-term occurrence of ischemic events in a previous study of patients treated with coronary stents would serve as a surrogate measure for adequate surgical hemostasis. 70, 71 Mean 24-hour chest tube drainage in clopidogrel-treated patients was 93% (95% CI, 81%-107%) of the amount observed in clopidogrel-naive patients, and the total amount of RBCs transfused did not differ between groups (1.80 U versus 2.08 U, respectively, P=0.540). It is notable that individualized waiting was 50% shorter than would have been recommended by current guidelines. 29 The benefits of an individualized waiting period were recently further corroborated by Mannacio et al 30 in patients undergoing off-pump CABG. The investigators evaluated the role of platelet function monitoring to define the optimal preoperative waiting time by comparing 100 patients undergoing individualized waiting with 2 propensity score-matched groups comprising 100 patients undergoing CABG after the recommended 5-day clopidogrel washout period and 100 clopidogrel-naive patients. In the individualized group, patients underwent CABG after complete recovery of platelet function as reflected by a closure time ≤106 seconds as assessed by the Innovance PFA2Y assay. Individualized waiting reduced bleeding (chest tube drainage and transfusion rate) and saved 280 days of total hospital stay in comparison with the recommended waiting period in the guidelines. In the individualized waiting group, overall length of hospital stay was 11.9±2.5 days in comparison with14.7±2.2 in the recommended 5-day waiting group (P<0.001).
Preoperative Platelet Function Monitoring to Guide Transfusion and Coagulation Management in Cardiac Surgery
The 2017 European Society of Cardiology guidelines on patient blood management for adult cardiac surgery recommend perioperative treatment algorithms based on point-of-care testing to reduce bleeding (Class IIa, Level B). However, cutoffs for the viscoelastic assays to trigger specific therapeutic interventions are not provided by these guidelines. Moreover, the cutoffs vary in the studies that are included in 2 meta-analyses and the multicenter trial supporting these guidelines. 14, [72] [73] [74] In the largest study thus far, Karkouti et al 73 recently demonstrated the benefits of such an algorithm sequentially implemented in consecutive patients undergoing cardiac surgery in 12 hospitals (Figure 3 ). Overall RBC transfusion was 45% with considerable variation between different hospitals. Major bleeding as defined by the Universal Definition of Bleeding occurred in 24.1% of the patients. In comparison with 3555 patients who underwent surgery during the control phase, implementation of the algorithm incorporating ROTEM and Plateletworks assays in 3847 patients during the intervention phase was associated with reduced transfusion of RBCs (relative risk, 0.91; 95% CI, 0.85-0.98) and platelets (relative risk, 0.77; 95% CI, 0.68-0.87) and major hemorrhage (relative risk, 0.83; 95% CI, 0.72-0.94) after adjusting for hospital, time of algorithm implementation, and prespecified patientspecific risk factors such as demographic variables, type and urgency of surgery, cardiopulmonary bypass time, use of cell salvage and tranexamic acid. 73 A limitation of the study by Karkouti et al is the absence of data on concomitant antiplatelet therapy.
In a randomized clinical trial including 76 patients on aspirin and 173 patients on aspirin and a P2Y 12 receptor inhibitor within 5 days preoperatively, Agarwal et al 75 investigated the value of preoperative platelet function testing as part of a transfusion algorithm on CABG-related bleeding. Patients undergoing urgent or emergent CABG were randomly assigned to preoperative platelet function monitoring with either Multiplate (group A) or TEG platelet mapping (group B), performed on the induction of anesthesia, or no preoperative testing (group C). Patients were managed according to a standardized protocol including transfusion triggers, routine tranexamic acid use, and postcardiopulmonary TEG assessment using kaolin and heparinase. In cases of postpump microvascular bleeding in groups A and B, the operating team was informed about preoperatively assessed platelet inhibition that, based on 2 arbitrarily defined cutoffs, triggered transfusion of 1 or 2 platelet pools. TEG (kaolin, heparinase, and functional fibrinogen) was then rechecked. Patients in group C underwent routine clinical management based solely on a postpump TEG measurement using kaolin and heparinase. In patients on DAPT, platelet function monitoring guided management and extended TEG evaluations and was associated with significantly reduced units of any transfusion and re-exploration for bleeding in comparison with control. Specifically, patients in groups A and B received fewer RBCs and coagulation proteins but more platelet pools than control patients. This beneficial effect was accompanied by cost savings of almost 50%. Despite accumulating evidence of an association between the extent of platelet inhibition and CABGrelated bleeding, the available literature suggests that factors like comorbidity, experience of the treating physicians, preoperative anemia, transfusion triggers and transfusion practice, use of cardiopulmonary bypass and cardiopulmonary bypass time, and use of antifibrinolytics and desmopressin contribute to surgery-related bleeding. 52, 59, 61, 69, 76, 77 Furthermore, the comparability of studies is limited because of the variable bleeding end points used (Table 3) . Moreover, validated absolute levels of platelet inhibition have not been established and may need to be as low as 20% to 40%, and the ideal assay to assess platelet inhibition remains elusive. 15 The 2012 update to the Society of Thoracic Surgeons guidelines states that "For patients on dual antiplatelet therapy, it is reasonable to make decisions about surgical delay in patients on dual antiplatelet therapy based on tests of platelet inhibition rather than arbitrary use of a specified period of delay" (Class IIa, Level B). 
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A10 indicates ROTEM variables assessed at 10 minutes; A10-EXTEM, clot amplitude at 10 minutes with the ROTEM extrinsic pathway assay: <35 mm implies impaired clot formation because of low fibrinogen levels or low platelet count; A10-FIBTEM, clot firmness amplitude at 10 minutes with ROTEM fibrinogen assay: ≤8 mm confirms low fibrinogen levels; ACT, activated clotting time; CPB, cardiopulmonary bypass; CT-EXTEM, clotting time with ROTEM extrinsic pathway assay: >90 s implies poor clot initiation possibly because of reduced coagulation factor levels or reduced thrombin generation; IBW, ideal body weight; IU, international units; POC, point-of-care tests; and ROTEM, rotation thromboelastometry. *Does not apply to red blood cell transfusions, which will be based on hemoglobin levels as per institutional practice. †If an additional protamine dose does not shorten ACT, consider low fibrinogen levels or an acquired deficiency of enzymatic coagulation factors as a reason for prolonged ACT and treat according to the algorithm (maximum overall protamine dose: 1.2 mg/100 U initial heparin dose). ‡If bleeding is severe, initiate treatment without weighing sponges and combine treatment steps as appropriate. §Unless bleeding is severe, treat in a stepwise manner and evaluate for effect after each step. ‖Consider 2 pools of platelets if massive bleeding, functioning platelets <15×10 9 /L or recent use of potent antiplatelet drugs. ¶Consider PCC (prothrombin complex concentrate), in particular, if right ventricular failure, volume overload, or recent warfarin use. Use plasma preferentially if FIBTEM is also low (≤10 mm) or massive bleeding. dromes recommend that, in patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding (Class I, Level B). These guidelines do not recommend preoperative platelet function monitoring 13 (Table 1) . Although bleeding cutoffs are currently not supported by large-scale studies, Figures 3 and 4 depict suggestions for implementing institutional algorithms to time surgery after individualized waiting and to specifically target postcardiopulmonary bypass bleeding in patients on DAPT by differentiating between the level of platelet inhibition and decreased coagulation proteins. 14, 22, 28, 73, 75 
Platelet Function Testing or Bridging in Patients at High Risk
Bridging oral antiplatelet therapy with intravenously applied reversible antiplatelet agents with a short half-life has been proposed in patients at high risk. 78 The BRIDGE study (Maintenance of Platelet Inhibition With Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery) evaluated the feasibility of intravenous cangrelor, a direct-acting reversible P2Y 12 inhibitor (half-life, 3 minutes), for bridging thienopyridine-treated patients to on-or off-pump CABG. Two hundred ten patients were randomly assigned to cangrelor or placebo. The median (interquartile range) duration of infusion was 2.8 (2.5-3.8) days for cangrelor and 3.4 (2.6-4.7) days for placebo. VerifyNow assessment was performed daily. Study drug infusion was discontinued 1 to 6 hours before CABG, and the last blood sample for evaluation of platelet inhibition was performed just before incision. In comparison with placebo, cangrelor consistently achieved and maintained platelet inhibition as assessed by VerifyNow at levels associated with a low risk of ischemic events, and platelet function recovered to normal before incision. Excessive bleeding was similar between the groups. However, it is important to note that the BRIDGE study was not powered to detect a difference in ischemia and bleeding. 79 As an alternative to cangrelor, intravenous glycoprotein IIb/IIIa inhibitors have also been suggested for bridging. Short-acting eptifibatide or tirofiban should be discontinued for at least 2 to 4 hours before surgery and abciximab for at least 12 hours before, to limit blood loss and transfusion. 13, 80, 81 However, both strategies need continuous intravenous access and surveillance and, as for cangrelor, there are no adequately powered clinical trial data to demonstrate the efficacy and safety of bridging with glycoprotein IIb/IIIa inhibitors. Moreover, the promising data supportive of platelet function measurements to time surgery challenge the need for bridging in most patients. Thus, at the present time, because of the lack of adequate data and the potential for bleeding associated with bridging parenteral antiplatelet agents, we do not recommend bridging during periods of withdrawal of oral antiplatelet drugs unless the risk of ischemia outweighs the risk of bleeding in the opinion of the treating physician. The latter should be undertaken on a case-by-case basis.
IS PLATELET TRANSFUSION EFFICACIOUS IN REVERSING THE ANTIPLATELET EFFECT OF P2Y 12 RECEPTOR INHIBITORS?
Although contradicted by clinical studies and experience, there is some inconsistency regarding the restoration of P2Y 12 receptor function by concentrated platelet transfusion. 9, 59, 75 In vitro experiments demonstrated a consistent concentration and time-dependent increase in platelet reactivity when blood from healthy volunteers treated with clopidogrel or prasugrel on top of aspirin was spiked with platelets but inconsistent efficacy with ticagrelor. [82] [83] [84] Moreover, a recent study in patients on maintenance therapy with aspirin and ticagrelor demonstrated that spiking blood with concentrated platelets resulted in meaningful restoration of platelet reactivity, albeit only 24 hours after the last dosing. 85 In contrast, in a randomized clinical trial including heathy volunteers receiving either one 180-mg dose of ticagrelor or one 600-mg dose of clopidogrel, it was recently demonstrated that, in comparison with no platelet transfusion, 1 autologous platelet apheresis unit administered 48 hours after ticagrelor resulted in an nonsignificant increase in platelet reactivity and a small, but significant, reversing effect at 48 hours after clopidogrel administration. 86 However, these results partially contrast to a small case series performed by our group in healthy volunteers on DAPT where vasodilator-stimulated phosphoprotein phosphorylation assay increased to 76% of pretreatment baseline within 2 hours after transfusion of 2 autologous platelet concentrates, whereas recovery of platelet aggregation as assessed by LTA was only observed 24 hours after transfusion. 87 The APTITUDE CABG study (Antagonize P2Y 12 Treatment Inhibitors by Transfusion of Platelets in an Urgent or Delayed Timing After Acute Coronary Syndrome or Percutaneous Coronary Intervention Presentation-Coronary Artery Bypass Graft) demonstrated that platelet transfusion resulted in a significant overall 21% relative increase of platelet reactivity in bleeding patients undergoing CABG during DAPT. However, platelet transfusion-induced platelet recovery was highly variable, an effect that may at least be explained by the low sample size in patients on prasugrel and ticagrelor. 88 
CONCLUSIONS
Although current guidelines issue Class IIa or IIb recommendations for preoperative platelet function assays, there is accumulating evidence of an association between enhanced platelet inhibition and increased CABG-related bleeding and the benefits of transfusion algorithms using objective measurements of platelet function. Larger prospective studies using standardized bleeding end points are needed to establish the utility of platelet function testing in the patient undergoing cardiac surgery who is treated with antiplatelet therapy. Moreover, validation of cutoffs to define high surgical bleeding risk is needed for each assay considered for use to guide surgical timing and perioperative bleeding management.
Patients at high risk may particularly benefit from preoperative platelet function monitoring to both guide individualized preoperative waiting and serve as part of a transfusion algorithm aiming at targeted postcardiopulmonary bypass hemostasis management. Individualized preoperative waiting time and intraoperative transfusion management are expected to substantially shorten length of stay and reduce costs. 
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